Combination Methotrexate And Gefitinib To Cure Ectopic Pregnancies: Phase I-II Clinical Trials
Funder
National Health and Medical Research Council
Funding Amount
$235,875.00
Summary
Ectopic pregnancies are dangerous emergencies that can cause fatal bleeding. Most require surgery. We plan to test a novel medication-based treatment that could be used to cure most ectopics. If successful, it could revolutionise current management.
Translating New Therapeutics And Diagnostics For Major Pregnancy Complications
Funder
National Health and Medical Research Council
Funding Amount
$481,156.00
Summary
My research is focussed on tackling major complications of pregnancy that are a threat to the lives of both mother’s and babies. We are developing new drug treatments for ectopic pregnancy (a dangerous condition where the pregnancy implants in the Fallopian tube), and preeclampsia (a condition where toxins leak out of the placenta into mum's blood, and can seriously injure many of mum's major organs). We are also generating a blood test that may help women avoid the tragedy of a stillbirth.
Development Of Vinorelbine As A Tablet Based Therapy To Cure Ectopic Pregnancies
Funder
National Health and Medical Research Council
Funding Amount
$361,594.00
Summary
Ectopic pregnancies occur if the pregnancy implants in the Fallopian tube. They can be deadly and most are treated surgically. We will examine the exciting possibility that instead of surgery, ectopic pregnancies may be cured with a tablet taken just once. We will perform laboratory studies and a clinical trial, giving vinorelbine to women with ectopic pregnancies.
Development Of Novel Medical Therapies To Cure Ectopic Pregnancies
Funder
National Health and Medical Research Council
Funding Amount
$601,156.00
Summary
Ectopic pregnancies are conceptions implanting outside the womb, mainly the fallopian tube. They are pathological, and can erode straight through the tube into large blood vessels causing fatal bleeding and death. We plan to assess three medication based approaches to treat this condition that would avoid surgery entirely. If we succeed, and subsequently translate one or more of these treatments to the clinic, it would revolutionise management of this serious gynaecological emergency.
Developing New Therapeutic Strategies For Brain Cancer
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
Each year, over 1,500 Australians will develop brain cancer. Unlike many cancers, it cannot be prevented by lifestyle changes. Adults with brain cancer usually die within 2 years. The overall aims of this funding are to extend patients' lives and build brain cancer research in Australia so that we have the best chance of curing this disease. The expected outcome is clinical trial of drug candidates for the most common and most deadly brain cancer, high-grade glioma.
Developing Molecularly Targeted Therapeutics And Diagnostics For Pregnancy Complications
Funder
National Health and Medical Research Council
Funding Amount
$321,489.00
Summary
Pregnancy complications still causes the death of mothers, and their babies. During this fellowship, we will be developing new treatments and clinical tests for three important complications of pregnancy. We will run clinical trials of a new medication based treatment to cure ectopic pregnancies. We will also develop a blood test that can identify those babies still in the womb but suffering dangerously low oxygen levels. Lastly, we will develop drugs to treat preeclampsia, a serious condition o ....Pregnancy complications still causes the death of mothers, and their babies. During this fellowship, we will be developing new treatments and clinical tests for three important complications of pregnancy. We will run clinical trials of a new medication based treatment to cure ectopic pregnancies. We will also develop a blood test that can identify those babies still in the womb but suffering dangerously low oxygen levels. Lastly, we will develop drugs to treat preeclampsia, a serious condition of pregnancy.Read moreRead less
The Role Of Osteocytes In Particle Induced Osteolysis
Funder
National Health and Medical Research Council
Funding Amount
$457,196.00
Summary
Hip replacements often fail due to the loss of adjacent bone. Metal or polyethylene particles are produced as the prosthesis bearing surface wears but how do these particles lead to bone loss? Our work suggests involvement of osteocytes within the bone mineral, which are increasingly understood to drive bone physiology and pathology. We will explore the role of the osteocytes by examining their response to particles, which may identify a new target to prevent particle-induced bone loss.
Many infants and children suffer from bowel motility disorders, for example, chronic constipation affects up to 1 in 10 children. However, the cause of many of these paediatric motility disorders remains unknown. In this project, we will examine the development of wiring of the nervous system that controls bowel motility. This is the first study to investigate the development of cell-cell communication during early stages of nervous system development.
Targeting Bone Marrow Lesions To Find Interventions In The Progression Of Osteoarthritis
Funder
National Health and Medical Research Council
Funding Amount
$467,395.00
Summary
It is essential to elucidate the underlying cause(s) of osteoarthritis because our current level of understanding of this condition has failed to produce effective treatments. Lesions in the bone under the cartilage (BMLs), seen using MRI, have strong potential value for the objective monitoring and management of OA. However, because the nature of BMLs is not well understood, the aim of this application is to perform a comprehensive study of BMLs in OA bone.
The Role Of Co-signalling Receptors In Cytotoxic Lymphocyte Activity During Infection And Cancer
Funder
National Health and Medical Research Council
Funding Amount
$739,657.00
Summary
Cytotoxic lymphocytes (CLs) are immune cells that detect and kill cancer cells. CLs recognise ‘stress’ proteins on cancer cells through specialised receptors, and this provides the signal for them to kill. However, some cancer cells, such as leukemic cells, can interfere with this recognition to avoid killing by immune cells. This project will investigate the mechanism of recognition and killing of cancer cells by CLs, using both mouse models and cells from patients with acute myeloid leukemia.